ImmunoPET imaging for solid tumors targeting Trop2
Trop2-targeted immunoPET Imaging of Solid Tumors
PHASE2; PHASE3 · RenJi Hospital · NCT06851663
This study is testing a new imaging method to see if it can help diagnose solid tumors like bladder and prostate cancer better than current methods.
Quick facts
| Phase | PHASE2; PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 400 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | RenJi Hospital (other) |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT06851663 on ClinicalTrials.gov |
What this trial studies
This study aims to optimize a new imaging method called Trop2-targeted immunoPET/CT for diagnosing solid tumors. It will evaluate the physiological and pathological distribution of imaging agents in various types of solid tumors, including bladder and prostate cancers. Patients with confirmed or suspected solid tumors will undergo whole-body scans after receiving a tracer injection, and the study will assess the diagnostic efficacy of this new imaging approach compared to conventional methods. The correlation between tumor uptake and Trop2 expression levels will also be analyzed.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18-75 with histologically confirmed or suspected solid tumors.
Not a fit: Patients who are pregnant or have severe hepatic and renal insufficiency may not benefit from this study.
Why it matters
Potential benefit: If successful, this imaging technique could improve the accuracy of diagnosing solid tumors, leading to better treatment decisions.
How similar studies have performed: While the approach is innovative, similar imaging techniques have shown promise in other studies, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18-75 year-old and of either sex * Histologically confirmed diagnosis of solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) or suspected solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) by diagnostic imaging; * Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol. Exclusion Criteria: * Pregnancy； * Severe hepatic and renal insufficiency; * Allergic to single-domain antibody radiopharmaceuticals.
Where this trial is running
Shanghai
- Renji Hospital, School of Medicine, Shanghai Jiao Tong University — Shanghai, China (RECRUITING)
Study contacts
- Principal investigator: Weijun Wei, Ph.D. & M.D. — Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
- Study coordinator: Weijun Wei, Ph.D. & M.D.
- Email: wwei@shsmu.edu.cn
- Phone: 15000083153
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Solid Tumor, Solid Carcinoma, Uroepithelial Carcinoma, Bladder Cancer, Prostate Cancer, Lung Cancer, Nasopharyngeal Cancer, Liver Cancer